NASDAQ:PCVX Vaxcyte (PCVX) Stock Price, News & Analysis → AI to Meet the Same Fate as EVs? (From Porter & Company) (Ad) Free PCVX Stock Alerts $69.03 +0.53 (+0.77%) (As of 03:22 PM ET) Add Compare Share Share Today's Range$67.55▼$69.6950-Day Range$60.57▼$81.0552-Week Range$34.11▼$82.04Volume229,765 shsAverage Volume869,485 shsMarket Capitalization$7.48 billionP/E RatioN/ADividend YieldN/APrice Target$78.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Vaxcyte alerts: Email Address Vaxcyte MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside13.0% Upside$78.50 Price TargetShort InterestBearish7.92% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.74Based on 6 Articles This WeekInsider TradingSelling Shares$8.72 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($4.18) to ($4.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.00 out of 5 starsMedical Sector810th out of 939 stocksBiological Products, Except Diagnostic Industry136th out of 154 stocks 2.5 Analyst's Opinion Consensus RatingVaxcyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $78.50, Vaxcyte has a forecasted upside of 13.0% from its current price of $69.49.Amount of Analyst CoverageVaxcyte has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.92% of the outstanding shares of Vaxcyte have been sold short.Short Interest Ratio / Days to CoverVaxcyte has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in Vaxcyte has recently increased by 1.54%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldVaxcyte does not currently pay a dividend.Dividend GrowthVaxcyte does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PCVX. Previous Next 3.7 News and Social Media Coverage News SentimentVaxcyte has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Vaxcyte this week, compared to 3 articles on an average week.Search Interest7 people have searched for PCVX on MarketBeat in the last 30 days. MarketBeat Follows6 people have added Vaxcyte to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vaxcyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,720,633.00 in company stock.Percentage Held by InsidersOnly 3.60% of the stock of Vaxcyte is held by insiders.Percentage Held by Institutions96.78% of the stock of Vaxcyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Vaxcyte are expected to decrease in the coming year, from ($4.18) to ($4.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxcyte is -16.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxcyte is -16.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxcyte has a P/B Ratio of 5.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. About Vaxcyte Stock (NASDAQ:PCVX)Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Read More PCVX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PCVX Stock News HeadlinesMarch 28, 2024 | insidertrades.comGrant Pickering Sells 15,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) StockMarch 22, 2024 | insidertrades.comAndrew Guggenhime Sells 8,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) StockMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 20, 2024 | finance.yahoo.comInsider Sell: Vaxcyte Inc (PCVX) CFO Andrew Guggenhime Sells 8,000 SharesMarch 16, 2024 | ca.finance.yahoo.comPCVX Jul 2024 70.000 putMarch 16, 2024 | ca.finance.yahoo.comPCVX Apr 2024 80.000 putMarch 16, 2024 | finance.yahoo.comPCVX Apr 2024 100.000 callMarch 12, 2024 | msn.comOracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For TuesdayMarch 28, 2024 | Crypto 101 Media (Ad)Top Project Outperforms BTC in 2023…According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.March 4, 2024 | finanznachrichten.deVaxcyte, Inc.: Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in InfantsMarch 4, 2024 | globenewswire.comVaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in InfantsMarch 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vaxcyte Amid Anticipation of Transformative VAX-31 Data ReleaseMarch 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vaxcyte on Strong Vaccine Candidate Prospects and Upward Financial ProjectionsFebruary 28, 2024 | markets.businessinsider.comVaxcyte’s VAX-31 Poised for Market Leadership: Shrader’s Bullish Forecast and Price Target UpdateFebruary 28, 2024 | markets.businessinsider.comTD Cowen Remains a Buy on Vaxcyte (PCVX)February 28, 2024 | finance.yahoo.comVaxcyte, Inc. (NASDAQ:PCVX) Q4 2023 Earnings Call TranscriptFebruary 27, 2024 | seekingalpha.comVaxcyte, Inc. 2023 Q4 - Results - Earnings Call PresentationFebruary 27, 2024 | globenewswire.comVaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 26, 2024 | benzinga.comVaxcyte Stock (NASDAQ:PCVX), Short Interest ReportFebruary 25, 2024 | insidermonkey.com5 Best Russell 2000 Stocks To Buy According To Hedge FundsFebruary 17, 2024 | finance.yahoo.comPCVX Apr 2024 50.000 callFebruary 17, 2024 | finance.yahoo.comPCVX Sep 2024 40.000 putFebruary 16, 2024 | finance.yahoo.comPCVX Mar 2024 90.000 callFebruary 16, 2024 | finance.yahoo.comPCVX Mar 2024 60.000 putFebruary 15, 2024 | finance.yahoo.comVaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024February 15, 2024 | globenewswire.comVaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024February 4, 2024 | ca.finance.yahoo.comPCVX Feb 2024 80.000 callSee More Headlines Receive PCVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxcyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today3/28/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:PCVX CUSIPN/A CIK1649094 Webwww.vaxcyte.com Phone650-837-0111FaxN/AEmployees254Year FoundedN/APrice Target and Rating Average Stock Price Target$78.50 High Stock Price Target$95.00 Low Stock Price Target$69.00 Potential Upside/Downside+14.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($4.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-402,270,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-32.04% Return on Assets-29.72% Debt Debt-to-Equity RatioN/A Current Ratio7.54 Quick Ratio7.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$13.04 per share Price / Book5.25Miscellaneous Outstanding Shares108,410,000Free Float104,505,000Market Cap$7.43 billion OptionableOptionable Beta0.91 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Grant E. Pickering M.B.A. (Age 56)Co-Founder, CEO & Director Comp: $1.1MMr. Andrew L. Guggenhime M.B.A. (Age 56)President & CFO Comp: $839.65kMr. James Wassil M.B.A. (Age 55)M.S., Executive VP & COO Comp: $826.3kMr. Mikhail Eydelman J.D. (Age 43)Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary Comp: $793.22kMr. Paul W. Sauer M.B.A. (Age 63)Senior Vice President of Process Development & Manufacturing Comp: $608.96kDr. Ashish Khanna M.B.A. (Age 52)Ph.D., Co-Founder Dr. Jeff Fairman Ph.D. (Age 60)Co-Founder & VP of Research Ms. Elvia Cowan (Age 51)Senior VP of Finance & Principal Accounting Officer Ms. Janet GraesserVice President of Corporate Communications & Investor RelationsMs. Whitney JonesChief People OfficerMore ExecutivesKey CompetitorsExelixisNASDAQ:EXELCRISPR TherapeuticsNASDAQ:CRSPHalozyme TherapeuticsNASDAQ:HALORevolution MedicinesNASDAQ:RVMDKrystal BiotechNASDAQ:KRYSView All CompetitorsInsiders & InstitutionsGrant PickeringSold 15,000 sharesTotal: $1.00 M ($66.93/share)PNC Financial Services Group Inc.Bought 1,411 shares on 3/22/2024Ownership: 0.006%Andrew GuggenhimeSold 8,000 sharesTotal: $552,160.00 ($69.02/share)Vanguard Group Inc.Bought 168,125 shares on 3/11/2024Ownership: 7.797%Wellington Management Group LLPSold 166,792 shares on 3/5/2024Ownership: 4.088%View All Insider TransactionsView All Institutional Transactions PCVX Stock Analysis - Frequently Asked Questions Should I buy or sell Vaxcyte stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vaxcyte in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PCVX shares. View PCVX analyst ratings or view top-rated stocks. What is Vaxcyte's stock price target for 2024? 5 Wall Street analysts have issued 12 month target prices for Vaxcyte's stock. Their PCVX share price targets range from $69.00 to $95.00. On average, they anticipate the company's share price to reach $78.50 in the next year. This suggests a possible upside of 13.0% from the stock's current price. View analysts price targets for PCVX or view top-rated stocks among Wall Street analysts. How have PCVX shares performed in 2024? Vaxcyte's stock was trading at $62.80 at the start of the year. Since then, PCVX stock has increased by 10.7% and is now trading at $69.49. View the best growth stocks for 2024 here. When is Vaxcyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our PCVX earnings forecast. How were Vaxcyte's earnings last quarter? Vaxcyte, Inc. (NASDAQ:PCVX) issued its quarterly earnings data on Tuesday, February, 27th. The company reported ($1.82) earnings per share for the quarter, missing analysts' consensus estimates of ($0.89) by $0.93. During the same period in the previous year, the company posted ($0.73) EPS. What ETFs hold Vaxcyte's stock? ETFs with the largest weight of Vaxcyte (NASDAQ:PCVX) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Alger 35 ETF (ATFV), Alger Mid Cap 40 ETF (FRTY), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Fidelity Disruptive Medicine ETF (FMED), SPDR S&P Biotech ETF (XBI) and Principal Healthcare Innovators ETF (BTEC). What other stocks do shareholders of Vaxcyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxcyte investors own include NVIDIA (NVDA), Twilio (TWLO), Boeing (BA), Overstock.com (OSTK), Pure Storage (PSTG), QUALCOMM (QCOM), Riot Platforms (RIOT), American Tower (AMT), Avid Technology (AVID) and CalAmp (CAMP). When did Vaxcyte IPO? Vaxcyte (PCVX) raised $210 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 14,000,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and Evercore ISI acted as the underwriters for the IPO and Cantor and Needham & Company were co-managers. Who are Vaxcyte's major shareholders? Vaxcyte's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.88%), Vanguard Group Inc. (7.80%), Wellington Management Group LLP (4.09%), Capital Research Global Investors (3.62%), Price T Rowe Associates Inc. MD (2.81%) and Jennison Associates LLC (1.55%). Insiders that own company stock include Andrew Guggenhime, Elvia Cowan, Grant Pickering, Heath Lukatch, Jane Wright-Mitchell, Jeff Fairman, Jim Wassil, Mikhail Eydelman and Paul Sauer. View institutional ownership trends. How do I buy shares of Vaxcyte? Shares of PCVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PCVX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.